Cell Genesys: Clinical Trials

10 trials sponsored by Cell Genesys, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 2 terminated, 2 unknown. 10 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 110Completed 6, Terminated 2, Unknown 2
Phase 28Completed 6, Terminated 1, Unknown 1

Follow Cell Genesys: new trials by email

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
GVAX in Advanced Prostate Cancer Patients Made Lymphopenic
GM-CSF gene transduced allogeneic vaccine GVAX - Prostate Cancer
Phase 1 / Phase 2UnknownProvidence Health & Services182005-07-012009-02-24
Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure
Oncolytic adenovirus (serotype 5) - CG0070 - Carcinoma, Transitional Cell, Bladder Neoplasms
Phase 1UnknownCell Genesys752005-04-012008-10-03
Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer
GVAX and ipilimumab - Prostate Cancer
Phase 1TerminatedAmsterdam UMC, location VUmc282004-11-012012-01-16
Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer
CG7870 - Prostate Cancer
Phase 1 / Phase 2TerminatedCell Genesys692004-08-012006-02-02
Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine
Immunotherapy allogeneic GM-CSF secreting cellular vaccine - Prostate Cancer
Phase 1 / Phase 2CompletedCell Genesys802001-12-012007-12-24
Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma
Therapeutic Cellular Vaccine, GM-CSF Producing - Multiple Myeloma
Phase 1 / Phase 2CompletedCell Genesys222000-10-012007-12-24
Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)
Immunotherapy allogeneic GM-CSF secreting cellular vaccine - Prostate Cancer
Phase 1 / Phase 2CompletedCell Genesys201999-05-012005-09-01
Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer
Immunotherapy allogeneic GM-CSF secreting cellular vaccine - Prostate Cancer
Phase 1 / Phase 2CompletedCell Genesys501999-05-012005-09-01
Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer)
Immunotherapy allogeneic GM-CSF secreting cellular vaccine - Prostate Cancer
Phase 1 / Phase 2CompletedCell Genesys361998-12-012005-09-01
Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer
CV787 (CG7870) - Prostate Cancer
Phase 1 / Phase 2CompletedCell Genesys2005-06-28

Conditions studied

Prostatic Neoplasms (8)  ·  Neoplasms (7)  ·  Neoplasm Metastasis (5)  ·  Adenoviridae Infections (1)  ·  Carcinoma in Situ (1)  ·  Carcinoma, Transitional Cell (1)  ·  Multiple Myeloma (1)  ·  Non-Muscle Invasive Bladder Neoplasms (1)  ·  Urinary Bladder Neoplasms (1)

Interventions

Ipilimumab (1)

Countries

United States (5)  ·  Canada (1)  ·  Netherlands (1)

Top investigators

Bernard Fox, PhD (1)  ·  Fons van den Eertwegh, MD PhD (1)  ·  Winald Gerritsen, Prof. MD PhD (1)

Results publications

PMID 22326922